Related Experiment Video
Updated: Dec 18, 2025
Preparation of Cytoplasmic and Nuclear Long RNAs from Primary and Cultured Cells
Published on: April 7, 2023
Selinexor for advanced hematologic malignancies
Janek S Walker1, Ramiro Garzon1, Rosa Lapalombella1
1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Abstract:
Recent measures to classify novel molecular targets with therapeutic potential across multiple hematologic tumors have identified the eukaryotic nuclear exporter, exportin 1 (XPO1), as a promising candidate. Molecular agents termed 'Selective Inhibitors of Nuclear Export' (SINEs) have been developed to selectively inhibit the essential regulatory functions of XPO1 in the eukaryotic cell and have been extensively studied in pre-clinical and clinical tumor models. Recently, selinexor (XPOVIO™), a first-in-class oral SINE molecule, was granted accelerated approval by the United States FDA for penta-refractory multiple myeloma. To establish a complete profile of this emerging drug candidate, this article reviews evidence collected from recent clinical studies against both solid and liquid tumors, describing selinexor as a promising new anti-cancer pharmaceutic against late-stage and highly aggressive tumors. With management of well-defined and predictable adverse effects, selinexor can be a life-saving therapeutic option in cancer patients with few alternatives.
Insights
Selinexor, a novel oral drug, targets exportin 1 (XPO1) to treat advanced cancers. This first-in-class Selective Inhibitor of Nuclear Export (SINE) shows promise as a life-saving option for patients with limited alternatives.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Exportin 1 (XPO1) is a key nuclear exporter identified as a therapeutic target in hematologic tumors.
- Selective Inhibitors of Nuclear Export (SINEs) are a class of molecular agents designed to inhibit XPO1 function.
- Selinexor (XPOVIO™) is the first oral SINE molecule approved for penta-refractory multiple myeloma.
Purpose of the Study:
- To review clinical evidence for selinexor in treating solid and liquid tumors.
- To establish a comprehensive profile of selinexor as an anti-cancer therapeutic.
- To assess selinexor's potential in late-stage and aggressive cancers.
Main Methods:
- Review of recent clinical studies involving selinexor.
- Analysis of pre-clinical and clinical tumor models.
- Evaluation of adverse effect management.
Main Results:
- Selinexor demonstrates potential as an anti-cancer pharmaceutical.
- The drug is effective against late-stage and highly aggressive tumors.
- Adverse effects are well-defined and predictable.
Conclusions:
- Selinexor represents a promising therapeutic option for cancer patients with limited treatment choices.
- Effective management of adverse effects supports its use in clinical practice.
- Selinexor offers a potential life-saving treatment for advanced cancers.
More Related Videos
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
08:29Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
Related Concept Videos
02:56Treatment Resistant Cancers
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...